This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	NF-κB	<p>Mouse and cell culture studies suggest pyrithione zinc and ouabain could be useful for treating AML. In a human AML cell line, the two compounds inhibited NF-κB-mediated prosurvival signaling and increased apoptosis compared with no treatment. In a mouse xenograft model of AML, the compounds significantly inhibited tumor growth compared with no treatment. Next steps include determining the therapeutic window and safety profiles of the molecules.</p> <p>Ouabain is a generic approved to treat heart failure. Pyrithione zinc is used in over-the-counter antidandruff and antiseborrhea products.</p> <p>SciBX 4(48); doi:10.1038/scibx.2011.1345 Published online Dec. 15, 2011</p>	Unpatented; unavailable for licensing	<p>Tailler, M. <i>et al. Oncogene</i>; published online Nov. 21, 2011; doi:10.1038/onc.2011.521</p> <p>Contact: O. Kepp, Gustave Roussy Institute, Villejuif, France e-mail: oliver.kepp@igr.fr</p> <p>Contact: G. Kroemer, same affiliation as above e-mail: kroemer@orange.fr</p>